Image Place holder

Damon Reed, MD

Program Leader, Adolescent Young Adult Program

Specialty: Medical Oncology
Program: Individualized Cancer Management

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Damon Reed is the Director of the Adolescent and Young Adult Program at Moffitt, the Medical Director of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida.  He is also an on staff as a specialty physician at All Children’s Hospital in St. Petersburg, FL. He is also the Leader of the Pediatric Cancer Foundation’s pediatric phase I consortium, the Sunshine Project. Dr. Reed’s research interests include chemotherapeutic approaches to sarcoma in the pediatric and adolescent and young adult population.  He is interested in establishing relevant preclinical sarcoma models, establishing and testing biomarkers for targeted therapies and translating predictive testing and combinations of agents towards personalized medicine in sarcoma and other rare cancers.   A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Children’s Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine.  He completed his fellowship training in pediatric hematology/oncology at St. Jude Children’s Research Hospital. Dr. Reed has received numerous academic awards, including graduating valedictorian from Canfield High School and summa cum laude from the University of Dayton.  He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology.  He joined Moffitt in 2008.

Education & Training

Board Certification:

  • Pediatric Hematology-Oncology

Fellowship:

  • St. Jude Children's Hospital - Pediatric Hematology Oncology
  • Harvard Medical School - Pediatrics

Residency:

  • Boston Children's Hospital - Pediatrics

Medical School:

  • Case Western University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 16962
A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors
Condition: Multiple
Intervention: CPT-11 (irinotecan); Camptosar (irinotecan); Metformin; Temodal (Temozolomide); Temozolomide; Vincristine; irinotecan
Open

CLINICAL TRIAL 18613
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Condition: Sarcoma
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); gemcitabine
Open

CLINICAL TRIAL 18937
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); Ifosfamide; Not Applicable; Pazopanib; doxorubicin
Open

CLINICAL TRIAL 18119
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Condition: Sarcoma
Intervention: G100; G305; LV305; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 18350
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
Condition: Sarcoma
Intervention: MESNA; NY-ESO-1c259T; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18821
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients with Potentially Resectable Soft Tissue Sarcoma Treated with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin Combination Therapy
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); Olaratumab; doxorubicin
Open

CLINICAL TRIAL 18940
The Complexity of Family-Centered Care: Identifying Support and Decision-Making Needs and Expectations of Young Adult Cancer Patients, Partner and Parent Caregivers
Condition: Multiple
Intervention:
Open

CLINICAL TRIAL 19003
A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone In Patients with Advanced Angiosarcoma (TAPPAS)
Condition: Sarcoma
Intervention: Pazopanib; TRC105
Open

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition: Gastrointestinal Tumor
Intervention: MGD007
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O, Brohl AS, Bridge JA, Stavas M, Shinohara ET, Meyer WH, Reed DR, Wagner LM. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. 2017 Sep. Pubmedid: 28905489.
  • Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Oct. Pubmedid: 28988646.
  • LaRosa KN, Stern M, Bleck J, Lynn C, Hudson J, Reed DR, Quinn GP, Donovan KA. Adolescent and Young Adult Patients with Cancer: Perceptions of Care. J Adolesc Young Adult Oncol. 2017 May. Pubmedid: 28537818.
  • Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun;123(12):2206-2218. Pubmedid: 28323337. Pmcid: PMC5485018.
  • Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Ne. 2017 Feb;15(2):155-167. Pubmedid: 28188186.
  • Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S. Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. J Adolesc Young Adult Oncol. 2017 Aug. Pubmedid: 28777007.
  • Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1089-1103. Pubmedid: 28651927.
  • Hoggard TM, Henderson-Jackson E, Bui MM, Caracciolo J, Teer JK, Yoder S, Binitie O, Gonzalez RJ, Brohl AS, Reed DR. Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy. BMC Cancer. 2017 Apr;17(1):250. Pubmedid: 28390395. Pmcid: PMC5385017.
  • Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep;122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
  • Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep. Pubmedid: 27621408.
  • Isenalumhe LL, Fridgen O, Beaupin LK, Quinn GP, Reed DR. Disparities in Adolescents and Young Adults With Cancer. Cancer Control. 2016 Oct;23(4):424-433. Pubmedid: 27842332.
  • Sreeraman Kumar R, Messina JL, Reed D, Navid F, Sondak VK. Pediatric Melanoma and Atypical Melanocytic Neoplasms. Cancer Treat Res. 2016 Jan;167:331-369. Pubmedid: 26601871.
  • Fridgen O, Sehovic I, Bowman ML, Reed D, Tamargo C, Vadaparampil S, Quinn GP. Contraception: the Need for Expansion of Counsel in Adolescent and Young Adult (AYA) Cancer Care. J Cancer Educ. 2016 Feb. Pubmedid: 26880356.
  • Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med. 2016 Feb;5(2):294-303. Pubmedid: 26714427. Pmcid: PMC4735769.
  • Kahen E, Yu D, Harrison DJ, Clark J, Hingorani P, Cubitt CL, Reed DR. Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. Cancer Chemother Pharmacol. 2016 Aug;78(2):313-323. Pubmedid: 27324022. Pmcid: PMC4965487.
  • Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S53-S56. Pubmedid: 27521325.
  • O'Shannessy DJ, Dai H, Mitchell M, Huntsman S, Brantley S, Fenstermacher D, Reed DR. Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies. Sarcoma. 2016 Apr;2016:5213628. Pubmedid: 27057137. Pmcid: PMC4748105.
  • Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Mody R, DuBois SG, Parsons DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05;209(5):182-194. Pubmedid: 27132463. Pmcid: PMC5497490.
  • Sondak VK, Reed D, Messina JL. A Comprehensive Approach to Pediatric Atypical Melanocytic Neoplasms with Comment on the Role of Sentinel Lymph Node Biopsy. Crit Rev Oncog. 2016;21(1-2):25-36. Pubmedid: 27481000.
  • Rejniak KA, Lloyd MC, Reed DR, Bui MM. Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. Med Hypotheses. 2015 Sep;85(3):348-354. Pubmedid: 26130106. Pmcid: PMC4549200.
  • DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R, Robinson L, Zager JS, Gonzalez RJ, Sondak VK, Letson GD, Conley A. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. PLoS One. 2015 Oct;10(10):e0140362. Pubmedid: 26469269. Pmcid: PMC4607370.
  • Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep. 2015 Nov;5:16991. Pubmedid: 26601688. Pmcid: PMC4658502.
  • Owens MA, Craig BM, Egan KM, Reed DR. Birth desires and intentions of women diagnosed with a meningioma. J Neurosurg. 2015 May;122(5):1151-1156. Pubmedid: 25623387. Pmcid: PMC4524337.
  • Quinn GP, Block RG, Clayman ML, Kelvin J, Arvey SR, Lee JH, Reinecke J, Sehovic I, Jacobsen PB, Reed D, Gonzalez L, Vadaparampil ST, Laronga C, Lee MC, Pow-Sang J, Eggly S, Franklin A, Shah B, Fulp WJ, Hayes-Lattin B. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract. 2015 Mar;11(2):137-144. Pubmedid: 25549654. Pmcid: PMC4799849.
  • Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul;112(1):103-106. Pubmedid: 26179670.
  • Quinn GP, Gonçalves V, Sehovic I, Bowman ML, Reed DR. Quality of life in adolescent and young adult cancer patients: a systematic review of the literature. Patient Relat Outcome Meas. 2015 Feb;6:19-51. Pubmedid: 25733941. Pmcid: PMC4337625.
  • Murphy D, Klosky JL, Reed DR, Termuhlen AM, Shannon SV, Quinn GP. The importance of assessing priorities of reproductive health concerns among adolescent and young adult patients with cancer. Cancer. 2015 Aug;121(15):2529-2536. Pubmedid: 26054052.
  • Shaw PH, Reed DR, Yeager N, Zebrack B, Castellino SM, Bleyer A. Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in Its Late Adolescence. J Pediat Hematol Onc. 2015 Apr;37(3):161-169. Pubmedid: 25757020.
  • Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014 Oct;32(29):3299-3306. Pubmedid: 25185097. Pmcid: PMC4588714.
  • Reed D, Block RG, Johnson R. Creating an adolescent and young adult cancer program: lessons learned from pediatric and adult oncology practice bases. J Natl Compr Canc Ne. 2014 Oct;12(10):1409-1415. Pubmedid: 25313180.
  • Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. J Clin Oncol. 2014 Nov;32(32):e107-e110. Pubmedid: 24550417.
  • Haddox CL, Han G, Anijar L, Binitie O, Letson GD, Bui MM, Reed DR. Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome. Sarcoma. 2014 Jun;2014:402509. Pubmedid: 24976784. Pmcid: PMC4021746.
  • Kim M, Reed D, Rejniak KA. The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study. J Theor Biol. 2014 Jul;352:31-50. Pubmedid: 24607745. Pmcid: PMC5483857.
  • Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, Frazier AL, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack B, Shead DA, Sundar H. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Ne. 2014 Jan;12(1):21-32. Pubmedid: 24453290.
  • Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R, Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep. 2014 Aug;16(8):395. Pubmedid: 24894064.
  • Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One. 2013 Sep;8(3):e57523. Pubmedid: 23520471. Pmcid: PMC3592874.
  • Kessler LM, Craig BM, Plosker SM, Reed DR, Quinn GP. Infertility evaluation and treatment among women in the United States. Fertil Steril. 2013 Oct;100(4):1025-1032. Pubmedid: 23849845. Pmcid: PMC3814221.
  • Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013 Nov;2013:365723. Pubmedid: 24282374. Pmcid: PMC3824404.
  • Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol. 2013 May;5:147-162. Pubmedid: 23700373. Pmcid: PMC3660127.
  • Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ. Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis. 2013 Mar;4:e566. Pubmedid: 23538447. Pmcid: PMC3613821.
  • Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol. 2013 Jun;3:141. Pubmedid: 23761859. Pmcid: PMC3674398.
  • Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Ne. 2013 Jun;11(6):679-686. Pubmedid: 23744867. Pmcid: PMC4530628.
  • Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia. 2013 Jun;29(1):1-7. Pubmedid: 23205633. Pmcid: PMC4509503.
  • Koohbanani B, Han G, Reed D, Zhao Q, Yi D, Henderson-Jackson E, Bui MM. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol. 2012 Oct;32(4):246-252. Pubmedid: 23043418.
  • Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, Raghavan M, Altiok S, Martinez GV, Gillies RJ. Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One. 2013 Dec;8(12):e82875. Pubmedid: 24358232. Pmcid: PMC3865096.
  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-382. Pubmedid: 23477833. Pmcid: PMC3766955.
  • Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. J Natl Compr Canc Netw. 2012 Sep;10(9):1112-1150. Pubmedid: 22956810.
  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov;19(12):3888-3895. Pubmedid: 22864798. Pmcid: PMC4519977.
  • Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 2012 Jan;11(1):174-182. Pubmedid: 22084170. Pmcid: PMC4545500.
  • Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ. Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor. Sarcoma. 2011 Jul;2011:971050. Pubmedid: 21647307. Pmcid: PMC3103998.
  • Reed D, Altiok S. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control. 2011 Jul;18(3):188-195. Pubmedid: 21666581.
  • Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010 Apr;285(14):10786-10796. Pubmedid: 20080970. Pmcid: PMC2856285.
  • Finelli DA, Reed DR. Flip angle dependence of experimentally determined T1sat and apparent magnetization transfer rate constants. J Magn Reson Imaging. 1998 May;8(3):548-553. Pubmedid: 9626867.